Elevated expression levels of immune checkpoints, such as PD-1, programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have been associated with enhanced clinical responses to ICB therapy in cancer patients, as demonstrated in prior studies.41 The gene discussed is CD274; the disease is cancer.